Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
21 Aprile 2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
22 Marzo 2021
Chiesi Group: performance is up in 2020
09 Marzo 2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
26 Febbraio 2021
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
01 Febbraio 2021
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
27 Gennaio 2021
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
14 Gennaio 2021
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
30 Novembre 2020
Chiesi Group receives Diversity Leaders Award 2021
19 Novembre 2020
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
